Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995369 | 0.75 | CDK4 (0.42) | CDK4CCND1NOTUMKMT2ABIRC5 | |
| SCHEMBL22769564 | 0.74 | CDK4 (0.45) | CDK4CCND1SLC6A2NOTUMKMT2A | |
| SCHEMBL17913218 | 0.73 | MGLL (0.44) | CDK4CCND1SLC6A2MAPT | |
| SCHEMBL321199 | 0.70 | CDK4 (0.45) | CDK4CCND1SLC6A2NOTUMMAPT | |
| SCHEMBL29614841 | 0.70 | CDK4 (0.45) | CDK4CCND1SLC6A2NOTUMMAPT | |
| SCHEMBL4288131 | 0.70 | CDK4 (0.45) | CDC7CDK2ROCK1CDK4CCND1 | |
| SCHEMBL6247012 | 0.69 | ALDH1A1 (0.41) | CDK4CCND1SLC6A2NOTUMMAPT | |
| Hydrochloric Acid SCHEMBL7218572 | 0.68 | CDK4 (0.43) | CDK4CCND1SLC6A2NOTUMMAPT | |
| SCHEMBL3576716 | 0.67 | CDK4 (0.47) | CDK4CCND1SLC6A2NOTUMKMT2A | |
| SCHEMBL10932323 | 0.67 | CDK4 (0.42) | CDK4CCND1NOTUMMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225619-B1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-10-14 | — | — | EP | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1934200-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934200-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | ABL1, MET, ERBB2 | CDC7 251/4885CDK2 117/4885ROCK1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.